Primate model to study reactivation of TB associated with retroviral infection

Future Virology

Volumn 5, Issue 4, 2010, Pages 391-395

  Lawn, Stephen D ^d   Wilkinson, Robert J ^a,b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

CHRONIC INFLAMMATION; DISEASE MODEL; DISEASE PREDISPOSITION; DISEASE SEVERITY; GRANULOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACACA; MIXED INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RETROVIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; T CELL DEPLETION; TUBERCULOSIS; VIRUS LOAD; VIRUS REACTIVATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA FASCICULARIS; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 77954941728     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.27     Document Type: Note

References (35)

1. Lawn SD, Churchyard G: Epidemiology of HIV-associated tuberculosis. Curr. Opin. HIV AIDS 4, 325-333 (2009).
2. Harries AD, Zachariah R, Corbett EL et at.: Confronting the HIV-associated tuberculosis epidemic - when will we act? Lancet 375, 1906-1919 (2010).
3. Flynn JL, Capuano SV, Croix D et at.: Non-human primates: a model for tuberculosi research. Tuberculosis 83, 116-118 (2003).
4. Orme IM: The mouse as a useful model of tuberculosis. Tuberculosis 83, 112-115 (2003).
5. Capuano SV 3rd, Croix DA, Pawar S et al.\ Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71, 5831-5844 (2003).
6. Lin PL, Pawar S, Myers A et al.\ Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 74, 3790-3803 (2006).
7. Lin PL, Rodgers M, Smith L et al: Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77, 4631-4642 (2009).
8. Lin PL, Myers A, Smith L et aL\ Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a Cynomolgus macaque model. Arthritis Rheum. 62, 340-350 (2010).
9. Diedrich CR, Mattila JT, Klein E et aL: Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS ONE 5, e9611 (2010).
10. Kalsdorf B, Scriba TJ, Wood K etal.: HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am. J. Respir. Crit. Care Med. 180, 1262-1270 (2009).
11. Beveridge NE, Price DA, Casazza JP et aL: Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis- specific CD4+ memory T lymphocyte populations. Eur. J. Immunol. 37, 3089-3100 (2007).
12. Lawn SD, Pisell TL, Hirsch CS, Wu M, Butera ST, Toossi Z: Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J. Infect. Dis. 184, 1127-1133 (2001).
13. Lawn SD, Butera ST, Shinnick TM: Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect. 4, 635-646 (2002).
14. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S: How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191, 150-158 (2005).
15. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P: Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 22, 1859-1867 (2008).
16. Holmes CB, Wood R, Badri M etaL: CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J. Acquir. ImmuneDefic. Syndr. 42, 464-469 (2006).
17. Yazdanpanah Y, Chene G, Losina E et aL: Incidence of primary opportunistic infections in two human immunodeficiency virus- infected French clinical cohorts. Int. J. Epidemiol. 30, 864-871 (2001).
18. Antonucci G, Girardi E, Raviglione MC, Ippolito G: Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 274, 143-148 (1995).
19. Markowitz N, Hansen NI, Hopewell PC et al.: Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann. Intern. Med. 126, 123-132 (1997).
20. Wood R, Liang H, Wu H et aL: Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int. J. Tuberc. Lung Dis. 14, 406-412 (2010).
21. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R: Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin. Infect. Dis. 42, 1040-1047 (2006).
22. Lawn SD, Kranzer K, Wood R: Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin. Chest Med. 30, 685-699 (2009).
23. Lawn SD, Bekker LG, Wood R: How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 19, 1113-1124 (2005).
24. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R: Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23, 1717-1725.
25. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373, 48-57 (2009).
26. von Reyn CF, Mtei L, Arbeit RD et aL: Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24, 675-685
27. Akolo C, Adetifa I, Shepperd S, Volmink J: Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst. Rev. 1, CD000171 (2010).
28. Whalen CC, Johnson JL, Okwera A et aL: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N. Engl. J. Med. 337, 801-808 (1997).
29. Jasmer RM, Saukkonen JJ, Blumberg HM et aL: Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann. Intern. Med. 137, 640-647 (2002).
30. Young DB, Gideon HP, Wilkinson RJ: Eliminating latent tuberculosis. Trends Microbiol. 17, 183-188 (2009).
31. Mtei L, Matee M, Herfort O et aL: High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin. Infect. Dis. 40, 1500-1507 (2005).
32. Dawson R, Masuka P, Edwards DJ et aL: Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int. J. Tuberc. Lung Dis. 14, 52-58 (2010).
33. Wood R, Middelkoop K, Myer L et aL: Undiagnosed tuberculosis in a community with high HIV-prevalence: implications for TB control. Am. J. Respir. Crit. Care Med 175, 87-93 (2007).
34. United Nations: The Millenium Development Goals Report 2008 "http://www.un.org/millenniumgoals/"
35. WHO: Global tuberculosis control. A short update to the 2009 report "http://www.who.int/tb/publications/globalreport/2009/update/tbu-9.pdf